Efficacy and Safety of Generic Alendronate for Osteoporosis Treatment

References

• Drake MT, Clarke BL, Lewiecki EM. The pathophysiology and treatment of osteoporosis. Clin Ther. 2015;37(8):1837–1850. doi:10.1016/j.clinthera.2015.06.006
   PubMed Web of Science ®Google Scholar
• Papaioannou A, Kennedy CC, Ioannidis G, et al. The impact of incident fractures on health-related quality of life: 5 years of data from the Canadian Multicentre Osteoporosis Study. Osteoporos Int. 2009;20(5):703–714. doi:10.1007/s00198-008-0743-7
   PubMed Web of Science ®Google Scholar
• Sattui SE, Saag KG. Fracture mortality: associations with epidemiology and osteoporosis treatment. Nat Rev Endocrinol. 2014;10(10):592–602. doi:10.1038/nrendo.2014.125
   PubMed Web of Science ®Google Scholar
• Hernlund E, Svedbom A, Ivergård M, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1):136. doi:10.1007/s11657-013-0136-1
   PubMed Web of Science ®Google Scholar
• Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29(11):2520–2526. doi:10.1002/jbmr.2269
   PubMed Web of Science ®Google Scholar
• Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the US preventive services task force. Ann Intern Med. 2002;137(6):529–541. doi:10.7326/0003-4819-137-6-200209170-00015
   PubMed Web of Science ®Google Scholar
• Tarride JE, Hopkins RB, Leslie WD, et al. The burden of illness of osteoporosis in Canada. Osteoporos Int. 2012;23(11):2591–2600. doi:10.1007/s00198-012-1931-z
   PubMed Web of Science ®Google Scholar
• Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475. doi:10.1359/jbmr.061113
   PubMed Web of Science ®Google Scholar
• Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32(2):198–202. doi:10.1002/jbmr.3051
   PubMed Web of Science ®Google Scholar
• Black DM, Rosen CJ. clinical practice. Postmenopausal osteoporosis. N Engl J Med. 2016;374(3):254–262. doi:10.1056/NEJMcp1513724
   PubMed Web of Science ®Google Scholar
• Sanderson J, Martyn-St James M, Stevens J, et al. Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis. Bone. 2016;89:52–58. doi:10.1016/j.bone.2016.05.013
   PubMed Web of Science ®Google Scholar
• Nayak S, Roberts MS, Greenspan SL. Impact of generic alendronate cost on the cost-effectiveness of osteoporosis screening and treatment. PLoS One. 2012;7(3):e32879. doi:10.1371/journal.pone.0032879
   PubMed Web of Science ®Google Scholar
• Cheung EYN, Tan KCB, Cheung CL, Kung AWC. Osteoporosis in East Asia: current issues in assessment and management. Osteoporos Sarcopenia. 2016;2(3):118–133. doi:10.1016/j.afos.2016.07.001
   PubMedGoogle Scholar
• You R, Liu Z. Economic evaluation of oral alendronate therapy for osteoporosis in Chinese postmenopausal women: the impact of medication compliance and persistence. Front Pharmacol. 2020;11:575893. doi:10.3389/fphar.2020.575893
   PubMed Web of Science ®Google Scholar
• Unnanuntana A, Jarusriwanna A, Songcharoen P. Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment. PLoS One. 2017;12(7):e0180325. doi:10.1371/journal.pone.0180325
   PubMed Web of Science ®Google Scholar
• Colombo GL, Montecucco CM. Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy. Clin Cases Miner Bone Metab. 2013;10(3):195–198.
   PubMedGoogle Scholar
• Lai PS, Chua SS, Chong YH, Chan SP. The effect of mandatory generic substitution on the safety of alendronate and patients’ adherence. Curr Med Res Opin. 2012;28(8):1347–1355. doi:10.1185/03007995.2012.708326
   PubMed Web of Science ®Google Scholar
• Brown JP, Davison KS, Olszynski WP, Beattie KA, Adachi JD. A critical review of brand and generic alendronate for the treatment of osteoporosis. Springerplus. 2013;2(1):550. doi:10.1186/2193-1801-2-550
   PubMedGoogle Scholar
• Charatcharoenwitthaya N, Jaisamrarn U, Songpatanasilp T, et al. Summary of the Thai Osteoporosis Foundation (TOPF) clinical practice guideline on the diagnosis and management of osteoporosis 2021. Osteoporos Sarcopenia. 2023;9(2):45–52. doi:10.1016/j.afos.2023.06.001
   PubMedGoogle Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract. 2020;26(Suppl 1):1–46.
   PubMed Web of Science ®Google Scholar
• Fatoye F, Smith P, Gebrye T, Yeowell G. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019;9(4):e027049. doi:10.1136/bmjopen-2018-027049
   PubMed Web of Science ®Google Scholar
• Cosman F, de Beur SJ, LeBoff MS, et al. Clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–2381. doi:10.1007/s00198-014-2794-2
   PubMed Web of Science ®Google Scholar
• Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112(4):281–289. doi:10.1016/S0002-9343(01)01124-X
   PubMed Web of Science ®Google Scholar
• Nayak S, Greenspan SL. Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. Osteoporos Int. 2020;31(7):1273–1282. doi:10.1007/s00198-019-05258-2
   PubMed Web of Science ®Google Scholar
• Cost-utility analysis of treatment for prevention of osteoporotic fractures [Internet]. Nonthaburi (TH): Health Intervention and Technology Assessment Program; [ cited August 8, 2023]. Available from: https://www.hitap.net/en/research/17703. Accessed February 16, 2024.
   Google Scholar
• Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25(10):2239–2250. doi:10.1002/jbmr.119
   PubMed Web of Science ®Google Scholar
• Duarte JW, Bolge SC, Sen SS. An evaluation of patients’ preferences for osteoporosis medications and their attributes: the PREFER-international study. Clin Ther. 2007;29(3):488–503. doi:10.1016/S0149-2918(07)80087-7
   PubMed Web of Science ®Google Scholar
• Sukchokpanich P, Anusitviwat C, Jarusriwanna A, Kitcharanant N, Unnanuntana A. Quality of life and depression status of caregivers of patients with femoral neck or intertrochanteric femoral fractures during the first year after fracture treatment. Orthop Surg. 2023;15(7):1854–1861. doi:10.1111/os.13802
   PubMed Web of Science ®Google Scholar
• Chen K, Wang T, Tong X, et al. Osteoporosis is associated with depression among older adults: a nationwide population-based study in the USA from 2005 to 2020. Public Health. 2023;226:27–31. doi:10.1016/j.puhe.2023.10.022
   PubMed Web of Science ®Google Scholar
• Zeng ZL, Xie H. Mesenchymal stem cell-derived extracellular vesicles: a possible therapeutic strategy for orthopaedic diseases: a narrative review. Biomater Transl. 2022;3(3):175–187. doi:10.12336/biomatertransl.2022.03.002
   PubMedGoogle Scholar
• Li X, Wang L, Huang B, et al. Targeting actin-bundling protein L-plastin as an anabolic therapy for bone loss. Sci Adv. 2020;6(47):eabb7135. doi:10.1126/sciadv.abb7135
   PubMed Web of Science ®Google Scholar
• Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9(5):382–387. doi:10.14740/jocmr2970w
   PubMedGoogle Scholar